| Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by … V Uchaipichat, PI Mackenzie, XH Guo, D Gardner-Stephen, A Galetin, ... Drug Metabolism and Disposition 32 (4), 413-423, 2004 | 378 | 2004 |
| Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data M Gertz, A Harrison, JB Houston, A Galetin Drug Metabolism and Disposition 38 (7), 1147-1158, 2010 | 334 | 2010 |
| PBPK models for the prediction of in vivo performance of oral dosage forms ES Kostewicz, L Aarons, M Bergstrand, MB Bolger, A Galetin, O Hatley, ... European Journal of Pharmaceutical Sciences 57, 300-321, 2014 | 330 | 2014 |
| Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data HM Jones, HA Barton, Y Lai, Y Bi, E Kimoto, S Kempshall, SC Tate, ... Drug Metabolism and Disposition 40 (5), 1007-1017, 2012 | 263 | 2012 |
| Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver X Chu, K Korzekwa, R Elsby, K Fenner, A Galetin, Y Lai, P Matsson, ... Clinical Pharmacology & Therapeutics 94 (1), 126-141, 2013 | 252 | 2013 |
| Isoform selectivity and kinetics of morphine 3-and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7 AN Stone, PI Mackenzie, A Galetin, JB Houston, JO Miners Drug Metabolism and Disposition 31 (9), 1086-1089, 2003 | 244 | 2003 |
| ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport‐mediated PK and DDIs in humans MJ Zamek‐Gliszczynski, CA Lee, A Poirier, J Bentz, X Chu, H Ellens, ... Clinical Pharmacology & Therapeutics 94 (1), 64-79, 2013 | 216 | 2013 |
| Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human … PJ Kilford, R Stringer, B Sohal, JB Houston, A Galetin Drug Metabolism and Disposition 37 (1), 82-89, 2009 | 204 | 2009 |
| Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism A Galetin, JB Houston Journal of Pharmacology and Experimental Therapeutics 318 (3), 1220-1229, 2006 | 201 | 2006 |
| CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions A Galetin, K Ito, D Hallifax, JB Houston Journal of Pharmacology and Experimental Therapeutics 314 (1), 180-190, 2005 | 194 | 2005 |
| Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition A Galetin, H Burt, L Gibbons, JB Houston Drug metabolism and disposition 34 (1), 166-175, 2006 | 191 | 2006 |
| Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant HS Brown, K Ito, A Galetin, JB Houston British journal of clinical pharmacology 60 (5), 508-518, 2005 | 177 | 2005 |
| Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine A Galetin, SE Clarke, JB Houston Drug Metabolism and Disposition 31 (9), 1108-1116, 2003 | 174 | 2003 |
| Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data PJ Kilford, M Gertz, JB Houston, A Galetin Drug Metabolism and Disposition 36 (7), 1194-1197, 2008 | 162 | 2008 |
| Methods for predicting in vivo pharmacokinetics using data from in vitro assays JB Houston, A Galetin Current drug metabolism 9 (9), 940-951, 2008 | 161 | 2008 |
| Clinical probes and endogenous biomarkers as substrates for transporter drug‐drug interaction evaluation: perspectives from the international transporter consortium X Chu, M Liao, H Shen, K Yoshida, AA Zur, V Arya, A Galetin, ... Clinical Pharmacology & Therapeutics 104 (5), 836-864, 2018 | 159 | 2018 |
| Prediction of in vivo drug-drug interactions from in vitro data HS Brown, A Galetin, D Hallifax, JB Houston Clinical pharmacokinetics 45 (10), 1035-1050, 2006 | 152 | 2006 |
| Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential M Gertz, CM Cartwright, MJ Hobbs, KE Kenworthy, M Rowland, ... Pharmaceutical research 30 (3), 761-780, 2013 | 147 | 2013 |
| Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction M Gertz, JB Houston, A Galetin Drug Metabolism and Disposition 39 (9), 1633-1642, 2011 | 146 | 2011 |
| Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction … CA Lee, MA O’Connor, TK Ritchie, A Galetin, JA Cook, ... Drug metabolism and disposition 43 (4), 490-509, 2015 | 145 | 2015 |
Amin Rostami-HodjeganProfessor of Systems Pharmacology, University of Manchester, UKVerified email at manchester.ac.uk
